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Evaluable Patients (N¼30)
Age at enrollment (years)
Mean(SD) 7.7 (4.7)
Median (range) 6.9 (2.2-17.3)
Age at enrollment (years)
2-3.99 10 (33%)
4 or older 20 (67%)
Stem Cell Source
Cord blood 5 (16%)
Marrow 21 (70%)
Marrow and cord blood 1 (3%)
PBSC 3 (10%)
Stage of Acute GI GVHD for





Overall Grade of Acute GVHD for
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medulloblastoma. Norovirus was detected by RNA RT-PCR
test of stool performed by Focus Diagnostics, Cypress, Ca. The
dose of Nitazoxanide was 100mg po BID for ages 1 to 4 years,
200 mg po BID for age 4 to 11 years, and 500 mg po BID for
greater than 11 years.
1 pt, 33 months post allo HSCT with normal immune
studies was not treated as symptoms resolved prior to test
result. All other pts clinically responded with improvements
in diarrhea, nausea, and abdominal pain in 2-4 days (median
2 days). 3 pts were pre-HSCT on chemo/immunotherapy and
11 were 17 days to 34 months after HSCT. All the treated pts
were on immune suppression or chemotherapy. 9 allo HSCT
pts were on immunosuppression and 5 of these had GVHD at
onset of symptoms. Immune suppression included tacroli-
mus/solumedrol (3), cellcept/solumedrol (2) plus inﬂiximab
(1), tacrolimus (1), cyclosporine (1), tacrolimus/cellcept (1). 3
pts were receiving immunotherapy (1), or chemotherapy for
solid tumors (2) prior to planned HSCT. 1 pt was 10 months
post auto HSCT. Clearance of stool virus was variable. 2/3 pts
treated prior to HSCT became negative on stool study within
5-14 days of treatment (1 unknown duration). Among pts
treated after HSCT 4/9 had persistent viral shedding, 2
received drug until death (1 adenovirus, 1 CHF) both were
treated greater than 2 months, 3 with GVHD still shed virus
after 6 months of treatment, and 4 are off therapy and
remain negative for norovirus RNA. 1 auto HSCT pt stopped
viral shedding 2 months post starting Nitazoxanide. 2 HSCT
pts with clinical resolution but persistent viral shedding
stopped treatment and had clinical symptoms return. These
pts responded to restarting therapy within 2 days but
continue to shed virus. UGI endoscopy/colonoscopy were
performed in 5 pts at the time of infection, all showed
inﬂammation/edema but no GVHD was seen on histology.
Peripheral blood CD4 counts among those with persistent
viral shedding ranged from <50-445/ul and for those that
cleared virus 143-1222/ul.
Nitazoxanide is effective therapy for norovirus gastroen-
teritis in immune compromised patients. Therapy needs to
be continued until stool RNA studies become negative.359
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Myeloablative regimens are associated with prolonged
periods of cachexia/anorexia, nausea/vomiting, mucositis,
and compromised gut integrity (CGI). Studies suggest that
CGI could increase the risk of developing acute Graft versus
Host Disease (aGVHD). Preserving gastrointestinal integritymay decrease the risk of aGVHD which occurs in approxi-
mately 35% of children undergoing allogeneic HCT. Probiotics
(nutritional supplements that contain viablemicroorganisms
and confer a beneﬁt to the host) have emerged as a possible
therapeutic agent in preserving gut integrity. Animal studies
have found that administration of probiotics reduced the
incidence of aGVHD when compared to placebo. Clinical
trials in children with HIV infections and adults receiving
organ transplants have found probiotics to reduce morbidity
andmortality. Prior to our Pilot Trial, probiotics had not been
investigated in the HCT setting. This pilot study evaluated the
safety and feasibility of probiotics administered to children
undergoing allogeneic HCT. Patients received once daily
supplementationwith L.plantarum 299v (1 x107 CFU/kg/day)
beginning on Day e 7 and continued until Day + 14. Thirty-
one patients who were undergoing myeloablative allogeneic
HCT were enrolled. One patient was not evaluated for safety
because only one dose was given and the patient withdrew
from the study. Safety: Of 30 evaluable patients, there were
no cases of Lactobacillus plantarum bacteremia (0% (0/30)
with 95% exact binomial CI (0%, 12%)). Feasibility: Of the 31
eligible patients, only one (#12) received < 50% of the dose.
Therefore, 97% of the eligible patients (30/31), 95% CI (83%-
100%), received at least 50% of the probiotic dose. Clos-
tridium difﬁcile infections were noted in 20% of the patients
by Day + 100. Non-lactobacillus bacteremia was noted in 23%
of evaluable patients. Three patients died before Day + 100,
but no deaths were associated with lactobacillus adminis-
tration. Stage 1-3 acute gastrointestinal aGVHD was noted in
22% of patients who survived to Day + 100. The overall
incidence of Grades II-III GVHD was 26%. No patients had
Grade 4 GVHD. Lactobacillus plantarum can safely and
feasibly be administered to children undergoing myeloa-
blative HCT.360
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Introduction: Patients undergoing hematopoietic cell
transplantation (HCT) have an increased risk of Clostridium
difﬁcile infection (CD). Literature reports CD infection in
nearly 20% of transplanted patients. No information about
this infection in HCT patients has been reported in Chile.
Patients and Methods: We performed a retrospective
analysis of 250 patients undergoing HCT at the Catholic
University Hospital in Santiago, Chile, between 2000 and
2013. Statistical analysis of the data was conducted using
SPSS Statistics v21.
Results: Of the 250 transplanted patients studied, 59%
(n¼147) were allo-HCT and 41% (n¼103) were auto-HCT. The
mean age was 39 years old (range, 15-69), with a male
predominance (151 patients; 60%). Main indications for HCT
were acute leukemia (n¼104; 42%), multiple myeloma
(n¼36; 14%) and lymphoma (n¼49; 20%). 93% of patients
received myeloablative (MA) regimens, and all of them
received proton pump inhibitors and prophylactic antibiotics
the previous months of the HCT. Of the 250 patients studied,
192 (77%) had at least one episode of diarrhea that required
study, among them 13% (n¼25) were documented as positive
for CD (toxin assay or PCR test), the mean age of this group
was 36 years old (range, 18-62), with a male predominance
(15 patients, 60%). All of the infected patients had mild to
moderate diseases and there were no deaths attributed to it.
80% (n¼20) of the infected patients underwent allo-HCT and
20% (n¼5) auto-HCT. In the allo-HCT group, 53% had acute
lymphoblastic leukemia, 6% acute myeloid leukemia, 24%
chronic myeloid leukemia and 12% other causes. In the
auto-HCT group, 40% were transplanted due to multiple
myeloma, 20% amyloidosis, 20% germinal cancer and 20%
acute myeloid leukemia. No patient required total central
parenteral nutrition previous to the infection. During the 3
months before HCT, 84% (n¼21) of the infected patients
used antibiotics including cephalosporins, carbapenem,
aminoglicosides and vancomycin. The overall incidence of CD
infection in the ﬁrst week, month and year after transplant,
was 4%, 6% and 10%, respectively, with a median time frame
from transplantation to infection diagnosis of 20 days. In
auto-HCT, 7 days, 30 days and 1 year CD incidence was 2, 3
and 5%, respectively. In allo-HCT, 7 days, 30 days and 1 year
CD incidence was 5, 9 and 14%, respectively. There was no
signiﬁcant statistical difference in overall survival (OS)
between the infected and non-infected patients one year
after the transplant (OS 68% for CD negative vs. 72% for CD
positive, p¼0.61).
Conclusions: In our institution CD infection in patients
undergoing HCT had a similar incidence to other reports.
Most of cases occur before the ﬁrst week after HCT (40% of
the cases), and the remained stable afterwards. We identiﬁed
the type of transplant (allo-HCT 3 times higher risk than
auto-HCT) and disease (ALL 3 times higher risk than AML) as
risk factors for CD infection.361
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hematologic malignancies and hematopoietic cell trans-
plantation (HCT). Optimal nutritional status is associated
with a shorter time of engraftment and less infection rates
during the initial phase. We present our experience in
nutritional assessment pre and post transplantation.
Objective: To evaluate the possible association between
nutritional parameters and outcomes such as overall survival
and speciﬁc complications, in patients who underwent HCT.
Patients and Methods: Retrospective study in patients with
HCT between June 2011 and May 2014 in our center. We
assessed nutritional status before transplantation and then
10 days after it. Nutritional assessment included anthro-
pometry, body mass index (BMI), albumin, prealbumin and
total urinary nitrogen (TUN). Statistical analysis was made
using IBP SSPS v.20.
Results:We studied a total of 50 patients between June 2011
andMay 2014. Media following time: 35months. Median age
was 41 years (18-67), 33 (66%) were male and 17 (33%)
female. Thirty two underwent (64%) allogeneic HCT and 18
(36%) autologous HSCT, with 42 undergoing (84%) myeloa-
blative conditioning and 8 (16%) reduced intensity condi-
tioning. Diagnoses included acute leukemia (26), lymphoma
(7), multiple myeloma (13), and aplastic anemia (3). Thirty
seven patients developed mucositis and 31 required paren-
teral nutrition (PN). Twenty three patients developed
mucositis and required PN (mild: 2, moderate: 20, severe: 1)
Incidence of mucositis between allogeneic and autologous
HCT that required PN was similar (75% vs 72%). Albumin
levels were 4,1mg/dL before and 3,3 mg/dL 10 days after
HSCT (p<0,05). No difference was found between BMI,
dynamometry and TUN before and after HCT. TUN before
HCT was associated with more days of PN (p<0,05). Multi-
variate analysis showed an association between lower
albumin levels after HCT and PN requirement, as well as a
longer length of stay. High TUN and lower albumin levels
after HCT were associated with longer platelet engraftment
time (p<0,05). Longer engrafment time was associated with
longer duration of PN (p<0,05). Nine patients (28%) in the
allogeneic group developed acute gastrointestinal graft
versus host disease (GVHD) that required prolonged PN. No
association was found between BMI, albumin, prealbumin,
TUN or requirement of PN, with the risk of mucositis or
infectious complications. None of the evaluated nutritional
parameters were associated with overall survive (OS).
Conclusion: High catabolism was associated with a longer
length of stay, the requirement of PN and a prolonged
platelet engraftment time. Acute gastrointestinal GVHD was
associated with more requirement and a longer duration of
PN. Nutritional parameters were not associated with any risk
of infection and OS.362
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Plerixafor (P) is highly effective at mobilizing peripheral
blood stem cells. Most centers, including our own, have an
algorithm that utilizes P in patients who are predicted to
have poor collections using G CSF alone, based on peripheral
